KIT genetic alterations in anorectal melanomas

Journal of Clinical Pathology

Volumn 68, Issue 2, 2015, Pages 130-134

  Santi, Raffaella ^a   Simi, Lisa ^b   Fucci, Rossella ^b   Paglierani, Milena ^a   Pepi, Monica ^a   Pinzani, Pamela ^b   Merelli, Barbara ^c   Santucci, Marco ^a   Botti, Gerardo ^d   Urso, Carmelo ^e   Massi, Daniela ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; TUMOR MARKER;

ADULT; AGED; ANORECTAL DISEASE; ANORECTAL MELANOMA; ARTICLE; CANCER SCREENING; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; CUTANEOUS MELANOMA; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; FRAMESHIFT MUTATION; GENE EXPRESSION; GENE MUTATION; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; HIGH RESOLUTION MELTING ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; METASTATIC MELANOMA; MISSENSE MUTATION; MUTATIONAL ANALYSIS; ONCOGENE C KIT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SEQUENCE ANALYSIS; VISCERAL METASTASIS; ANUS TUMOR; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; GENETICS; INTESTINE MUCOSA; ITALY; MIDDLE AGED; MULTICENTER STUDY; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PREDICTIVE VALUE; RECTUM TUMOR; SECONDARY; SKIN TUMOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANUS NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INTESTINAL MUCOSA; ITALY; MALE; MELANOMA; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS C-KIT; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84922188067     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2014-202572     Document Type: Article

References (42)

1. Lens M, Bataille V, Krivokapic Z. Melanoma of the small intestine. Lancet Oncol 2009;10:516-21.
2. Patel JK, Didolkar MS, Pickren JW, et al. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg 1978;135:807-10.
3. de la Monte SM, Moore GW, Hutchins GM. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res 1983;43:3427-33.
4. Ihde JK, Coit DG. Melanoma metastatic to stomach, small bowel, or colon. Am J Surg 1991;162:208-11.
5. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998;83:1664-78.
6. Manouras A, Genetzakis M, Lagoudianakis E, et al. Malignant gastrointestinal melanomas of unknown origin: should it be considered primary? World J Gastroenterol 2007;13:4027-9.
7. Patrick RJ, Fenske NA, Messina JL. Primary mucosal melanoma. J Am Acad Dermatol 2007;56:828-34.
8. Romano E, Schwartz GK, Chapman PB, et al. Treatment implications of the emerging molecular classification system for melanoma. Lancet Oncol 2011;12:913-22.
9. Scolyer RA, Long GV, Thompson JF. Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. Mol Oncol 2011;5:124-36.
10. Quintás-Cardama A, Lazar AJ, Woodman SE, et al. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol 2008;5:737-40.
11. Hodi FS, Friedlander P, Corless CL, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008;26:2046-51.
12. Lutzky J, Bauer J, Bastian BC. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 2008;21:492-3.
13. Woodman SE, Trent JC, Stemke-Hale K, et al. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 2009;8:2079-85.
14. Satzger I, Küttler U, Völker B, et al. Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy - case report and review of the literature. Dermatology 2010;220:77-81.
15. Garrido MC, Bastian BC. KIT as a therapeutic target in melanoma. J Invest Dermatol 2010;130:20-7.
16. Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011;305:2327-34.
17. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24:4340-6.
18. Antonescu CR, Busam KJ, Francone TD, et al. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 2007;121:257-64.
19. Beadling C, Jacobson-Dunlop E, Hodi FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008;14:6821-8.
20. Satzger I, Schaefer T, Kuettler U, et al. Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas. Br J Cancer 2008;99:2065-9.
21. Rivera RS, Nagatsuka H, Gunduz M, et al. C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch 2008;452:27-32.
22. Torres-Cabala CA, Wang WL, Trent J, et al. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol 2009;22:1446-56.
23. Handolias D, Hamilton AL, Salemi R, et al. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. Br J Cancer 2010;102:1219-23.
24. Abysheva SN, Iyevleva AG, Efimova NV, et al. KIT mutations in Russian patients with mucosal melanoma. Melanoma Res 2011;21:555-9.
25. Langer R, Becker K, Feith M, et al. Genetic aberrations in primary esophageal melanomas: molecular analysis of c-KIT, PDGFR, KRAS, NRAS and BRAF in a series of 10 cases. Mod Pathol 2011;24:495-501.
26. Omholt K, Grafström E, Kanter-Lewensohn L, et al. KIT pathway alterations in mucosal melanomas of the vulva and other sites. Clin Cancer Res 2011;17:3933-42.
27. Yun J, Lee J, Jang J, et al. KIT amplification and gene mutations in acral/mucosal melanoma in Korea. APMIS 2011;119:330-5.
28. Kong Y, Si L, Zhu Y, et al. Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res 2011;17:1684-91.
29. Abu-Abed S, Pennell N, Petrella T, et al. KIT gene mutations and patterns of protein expression in mucosal and acral melanoma. J Cutan Med Surg 2012;16:135-42.
30. Ni S, Huang D, Chen X, et al. C-kit gene mutation and CD117 expression in human anorectal melanomas. Hum Pathol 2012;43:801-7.
31. Minor DR, Kashani-Sabet M, Garrido M, et al. Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res 2012;18:1457-63.
32. Schoenewolf NL, Bull C, Belloni B, et al. Sinonasal, genital and acrolentiginous melanomas show distinct characteristics of KIT expression and mutations. Eur J Cancer 2012;48:1842-52.
33. Park E, Yang S, Emley A, et al. Lack of correlation between immunohistochemical expression of cKIT and KIT mutations in atypical acral nevi. Am J Dermatopathol 2012;34:41-6.
34. Alexis JB, Martinez AE, Lutzky J. An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients. Melanoma Res 2005;15:283-5.
35. Blecker D, Abraham S, Furth EE, et al. Melanoma in the gastrointestinal tract. Am J Gastroenterol 1999;94:3427-33.
36. Zhao J, Quan H, Xu Y, et al. Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants. Cancer Sci 2014;105:117-25.
37. Hodi FS, Corless CL, Giobbie-Hurder A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol 2013;31:3182-90.
38. Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011;29:2904-9.
39. Lefevre G, Glotin AL, Calipel A, et al. Roles of stem cell factor/c-Kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis. J Biol Chem 2004;279:31769-79.
40. Smalley KS, Contractor R, Nguyen TK, et al. Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. Cancer Res 2008;68:5743-52.
41. Ashida A, Takata M, Murata H, et al. Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int J Cancer 2009;124:862-8.
42. Carvajal RD. Another option in our KIT of effective therapies for advanced melanoma. J Clin Oncol 2013;31:3173-5.